HIN 0.00% $2.37 heartware international, inc

Thoratec (THOR) Down

  1. 4,131 Posts.
    http://www.nasdaq.com/article/thora...ll-on-growing-headwinds-analyst-blog-cm413451
    The revenue drop was primarily due to the decline in HeartMate II sales, partially offset by continued double-digit revenue growth in the CentriMag business. Third-quarter revenues of $105.8 million also lagged the Zacks Consensus Estimate of $108 million.

    The company also slashed its adjusted earnings and revenue guidance owing to lower assumptions for HeartMate II product line on the back of near-term challenges. Thoratec anticipates higher operating expenses in the fourth quarter of 2014 due to accelerated clinical trial activity, targeted commercial investments, and product development project expenses.
 
watchlist Created with Sketch. Add HIN (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.